Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 149 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adverse Drug Events Clear all
Suspended Not applicable Interventional

Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)

NCT01305148
View directory record Official record
Conditions
Anti-coagulation Therapy, DVT, Pulmonary Embolism, Joint Surgery Multiple, Atrial Fibrillation, Prosthetic Replacement of Mitral Valve
Interventions
Warfarin GenoSTAT Test
Device
Lead sponsor
Iverson Genetic Diagnostics, Inc.
Industry
Eligibility
65 Years and older
Enrollment
3,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
56
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Pharmacogenetics to Identify Patients With Polypharmacy at Risk of Medication Adverse Effects

NCT03748355
View directory record Official record
Conditions
Psychiatric Disorder
Interventions
Pharmacogentic Analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Early Phase 1 Interventional

Studies of Sulfur Metabolism in Humans

NCT03383133
View directory record Official record
Conditions
Metabolic Side Effects of Drugs
Interventions
SULT Allosteric Inhibition
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
61 Years to 61 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Reduction of Adverse Drug Events and Readmissions

NCT02738047
View directory record Official record
Conditions
Pharmacogenomic Testing for Medication Management
Interventions
Not listed
Lead sponsor
ClinLogic LLC
Industry
Eligibility
25 Years and older
Enrollment
280,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-8736, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1 Interventional

Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

NCT01439152
View directory record Official record
Conditions
Oncology
Interventions
BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
8
States / cities
New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants

NCT06673238
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-722, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Cypress, California • Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Not yet recruiting Phase 2 Interventional

The CARDIOPROTECT Trial

NCT07654426
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
Interventions
Dexrazoxane, Dexrazoxane placebo, Doxorubicin, Liposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone, Rituximab, Polatuzumab Vedotin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:

NCT06322238
View directory record Official record
Conditions
Pharmacogenomic Drug Interaction, Side Effect of Drug, Ineffective Drug Action, Drug Metabolism, Poor, CYP2D6-Related, Drug Metabolism, Poor, CYP2C19-Related
Interventions
PGx panel test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
View directory record Official record
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Improving Wisely - Polypharmacy

NCT03857100
View directory record Official record
Conditions
Adverse Drug Event
Interventions
Audit and feedback - letter and report
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
11,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PK of Depo SubQ Injected in the Upper Arm

NCT01143207
View directory record Official record
Conditions
Contraception
Interventions
Medroxyprogesterone acetate
Drug
Lead sponsor
FHI 360
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Jul 21, 2026, 11:10 AM EDT
Terminated Phase 4 Interventional Results available

Naltrexone/Bupropion Cardiovascular Outcomes Study

NCT02638129
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Naltrexone HCl/Bupropion HCl ER, Placebo
Drug
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
139
States / cities
Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing the Safety of Warfarin in Nursing Homes

NCT00682773
View directory record Official record
Conditions
Adverse Drug Events (ADEs)
Interventions
SBAR
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
2
States / cities
Middletown, Connecticut • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge

NCT01806038
View directory record Official record
Conditions
Drug Related Problems Post Hospital Discharge, Healthcare Utilization, Discharge Medication Counseling
Interventions
RPh Counseling + Outpatient Med Dispensing at Discharge, Discharge Med Dispensing Plus Counseling - Current Practice
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2014 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting No phase listed Observational

The Texas Interprofessional Pharmacogenomics (IPGx)

NCT06219720
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Not listed
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
50 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bryan, Texas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional

Patient Profiling and Provider Feedback to Reduce Adverse Drug Events

NCT00013143
View directory record Official record
Conditions
Adverse Drug Events
Interventions
Patient risk profiling (potential ADEs) w/provider feedback
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 21, 2026, 11:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

NCT06100744
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Adalimumab, Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
5 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Little Rock, Arkansas • Washington D.C., District of Columbia • Hollywood, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Active, not recruiting Early Phase 1 Interventional

Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction

NCT04676399
View directory record Official record
Conditions
Chronic Pain, Hypertension, Diuretics Drug Reactions, SCS
Interventions
Hydrochlorothiazide 12.5mg, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
40 Years to 79 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics

NCT00229671
View directory record Official record
Conditions
Pediatric ALL
Interventions
Survey 1, Survey 2
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
1 Day to 21 Years
Enrollment
6,341 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

NCT04255433
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Tirzepatide, Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
40 Years and older
Enrollment
13,299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
121
States / cities
Birmingham, Alabama • Concord, California • Covina, California + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

NCT03345485
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 21, 2026, 11:10 AM EDT
Completed No phase listed Observational

YouScript IMPACT Registry

NCT02191358
View directory record Official record
Conditions
Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions
Not listed
Lead sponsor
Genelex Corporation
Industry
Eligibility
65 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
7
States / cities
Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jul 21, 2026, 11:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

PREventing Adverse Events Post-Discharge Through Proactive Identification, Multidisciplinary Communication, and Technology

NCT05232656
View directory record Official record
Conditions
Transitions of Care, General Medicine, Discharge Checklist, Adverse Event
Interventions
Pre-Discharge Checklist and Patient Safety Dashboard
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Jul 21, 2026, 11:10 AM EDT